Table 3.
Namibia | South Africa | Uganda | Zambia | All sites | All sites - FU up to 18 months | All sites - if alive at 18 months |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model | HIV status | Deaths | HR (95% CI) | Deaths | HR (95% CI) | Deaths | HR (95% CI) | Deaths | HR (95% CI) | Deaths | HR (95% CI) | Deaths | HR (95% CI) | Deaths | HR (95% CI) |
Crude | HIV− | 118 | 1·00 | 125 | 1·00 | 157 | 1·00 | 32 | 1·00 | 432 | 1·00 | 269 | 1·00 | 163 | 1·00 |
HIV+ | 25 | 1·14 | 62 | 1·47 | 29 | 1·09 | 21 | 2·23 | 137 | 1·35 | 87 | 0·95 | 50 | 1·4 | |
(0·74–1·76) | (1·09–2·00) | (0·73–1·61) | (1·29–3·87) | (1·11–1·63) | (0·74–1·22) | (1·02–1·93) | |||||||||
+ Age | HIV− | 118 | 1·00 | 125 | 1·00 | 157 | 1·00 | 32 | 1·00 | 432 | 1·00 | 269 | 1·00 | 163 | 1·00 |
HIV+ | 25 | 1·23 | 62 | 1·67 | 29 | 1·14 | 21 | 2·87 | 137 | 1·46 | 87 | 0·99 | 50 | 1·48 | |
(0·79–1·92) | (1·20–2·31) | (0·76–1·70) | (1·57–5·25) | (1·19–1·78) | (0·77–1·28) | (1·06–2·06) | |||||||||
+ Stage | HIV− | 118 | 1·00 | 125 | 1·00 | 157 | 1·00 | 32 | 1·00 | 432 | 1·00 | 269 | 1·00 | 163 | 1·00 |
HIV+ | 25 | 1·39 | 62 | 1·58 | 29 | 1·10 | 21 | 3·12 | 137 | 1·46 | 87 | 0·97 | 50 | 1·53 | |
(0·88–2·19) | (1·14–2·20) | (0·73–1·66) | (1·66–5·87) | (1·19–1·79) | (0·75–1·27) | (1·09–2·15) | |||||||||
+ Other factors γ | HIV− | 118 | 1·00 | 123 | 1·00 | 157 | 1·00 | 32 | 1·00 | 430 | 1·00 | 266 | 1·00 | 163 | 1·00 |
HIV+ | 25 | 1·26 | 61 | 1·61 | 29 | 1·09 | 21 | 3·10 | 136 | 1·41 | 85 | 0·98 | 50 | 1·48 | |
(0·79–2·03) | (1·14–2·28) | (0·72–1·65) | (1·64–5·88) | (1·15–1·74) | (0·75–1·29) | (1·06–2·08) | |||||||||
+ Receptor subtypes | HIV− | 112 | 1·00 | 120 | 1·00 | ·· | ·· | ·· | ·· | 232 | 1·00 | 141 | 1·00 | 91 | 1·00 |
HIV+ | 25 | 1·36 | 59 | 1·54 | ·· | ·· | ·· | ·· | 84 | 1·43 | 50 | 1·22 | 34 | 1·56 | |
(0·84–2·20) | (1·08–2·20) | ·· | ·· | ·· | ·· | (1·08–1·88) | (0·83–1·79) | (1·01–2·40) |
To a simple model with HIV status as the only exposure, each of the other factors were added sequentially to the model one at a time i.e. age, then stage etc.
Other factors include tumour grade, educational level and socio economic position